Lazard Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $95.2M | Buy |
213,131
+14,181
| +7% | +$6.61M | 0.16% | 138 |
|
|
2025
Q4 | $90.2M | Sell |
198,950
-345,873
| -63% | -$149M | 0.15% | 148 |
|
|
2025
Q3 | $213M | Buy |
544,823
+64,513
| +13% | +$27M | 0.29% | 84 |
|
|
2025
Q2 | $214M | Sell |
480,310
-52,287
| -10% | -$24.1M | 0.29% | 79 |
|
|
2025
Q1 | $258M | Buy |
532,597
+6,478
| +1% | +$3.02M | 0.4% | 69 |
|
|
2024
Q4 | $212M | Buy |
526,119
+518,132
| +6,487% | +$240M | 0.31% | 73 |
|
|
2024
Q3 | $3.71M | Sell |
7,987
-114,469
| -93% | -$55M | 0.01% | 715 |
|
|
2024
Q2 | $57.4M | Sell |
122,456
-1,427
| -1% | -$619K | 0.07% | 198 |
|
|
2024
Q1 | $51.8M | Buy |
123,883
+4,094
| +3% | +$1.73M | 0.06% | 223 |
|
|
2023
Q4 | $48.7M | Buy |
119,789
+833
| +0.7% | +$308K | 0.06% | 215 |
|
|
2023
Q3 | $41.4M | Sell |
118,956
-760
| -0.6% | -$266K | 0.06% | 233 |
|
|
2023
Q2 | $42.1M | Sell |
119,716
-7,814
| -6% | -$2.63M | 0.05% | 239 |
|
|
2023
Q1 | $40.2M | Sell |
127,530
-14,911
| -10% | -$4.47M | 0.05% | 262 |
|
|
2022
Q4 | $41.1M | Sell |
142,441
-481,400
| -77% | -$147M | 0.06% | 256 |
|
|
2022
Q3 | $181M | Sell |
623,841
-240,065
| -28% | -$69.1M | 0.26% | 77 |
|
|
2022
Q2 | $243M | Sell |
863,906
-33,936
| -4% | -$9.08M | 0.33% | 68 |
|
|
2022
Q1 | $234M | Sell |
897,842
-17,878
| -2% | -$4.24M | 0.27% | 77 |
|
|
2021
Q4 | $201M | Buy |
915,720
+749,784
| +452% | +$146M | 0.21% | 91 |
|
|
2021
Q3 | $30.1M | Buy |
165,936
+24,195
| +17% | +$4.72M | 0.03% | 383 |
|
|
2021
Q2 | $28.6M | Buy |
141,741
+25,856
| +22% | +$5.41M | 0.03% | 384 |
|
|
2021
Q1 | $24.9M | Sell |
115,885
-16,224
| -12% | -$3.56M | 0.03% | 388 |
|
|
2020
Q4 | $31.2M | Sell |
132,109
-74,073
| -36% | -$17M | 0.04% | 344 |
|
|
2020
Q3 | $56.1M | Buy |
206,182
+5,959
| +3% | +$1.64M | 0.08% | 199 |
|
|
2020
Q2 | $58.1M | Buy |
200,223
+141,600
| +242% | +$38.4M | 0.09% | 176 |
|
|
2020
Q1 | $13.9M | Buy |
58,623
+3,264
| +6% | +$749K | 0.03% | 370 |
|
|
2019
Q4 | $12.1M | Buy |
55,359
+1,027
| +2% | +$208K | 0.02% | 424 |
|
|
2019
Q3 | $9.2M | Sell |
54,332
-24,198
| -31% | -$4.28M | 0.02% | 470 |
|
|
2019
Q2 | $14.4M | Sell |
78,530
-7,697
| -9% | -$1.35M | 0.02% | 393 |
|
|
2019
Q1 | $15.9M | Buy |
86,227
+53,177
| +161% | +$9.82M | 0.03% | 340 |
|
|
2018
Q4 | $5.48M | Sell |
33,050
-5,937
| -15% | -$1.03M | 0.01% | 516 |
|
|
2018
Q3 | $7.51M | Buy |
38,987
+7,252
| +23% | +$1.29M | 0.01% | 498 |
|
|
2018
Q2 | $5.39M | Sell |
31,735
-127,772
| -80% | -$19.8M | 0.01% | 548 |
|
|
2018
Q1 | $26M | Sell |
159,507
-14,479
| -8% | -$2.36M | 0.04% | 269 |
|
|
2017
Q4 | $26.1M | Buy |
173,986
+564
| +0.3% | +$83.5K | 0.04% | 259 |
|
|
2017
Q3 | $26.4M | Sell |
173,422
-27,745
| -14% | -$4.18M | 0.05% | 248 |
|
|
2017
Q2 | $25.9M | Sell |
201,167
-254,906
| -56% | -$30.7M | 0.05% | 249 |
|
|
2017
Q1 | $49.9M | Sell |
456,073
-269,331
| -37% | -$23.7M | 0.09% | 151 |
|
|
2016
Q4 | $53.4M | Sell |
725,404
-472,069
| -39% | -$38.4M | 0.11% | 141 |
|
|
2016
Q3 | $104M | Sell |
1,197,473
-68,285
| -5% | -$6.45M | 0.21% | 90 |
|
|
2016
Q2 | $109M | Buy |
1,265,758
+283,415
| +29% | +$24.5M | 0.23% | 93 |
|
|
2016
Q1 | $78.1M | Buy |
982,343
+196,933
| +25% | +$17.8M | 0.17% | 114 |
|
|
2015
Q4 | $98.8M | Sell |
785,410
-462,435
| -37% | -$55.8M | 0.23% | 101 |
|
|
2015
Q3 | $130M | Sell |
1,247,845
-683,511
| -35% | -$87.8M | 0.31% | 84 |
|
|
2015
Q2 | $238M | Sell |
1,931,356
-154,185
| -7% | -$19.4M | 0.5% | 54 |
|
|
2015
Q1 | $246M | Sell |
2,085,541
-249,418
| -11% | -$29.9M | 0.53% | 53 |
|
|
2014
Q4 | $277M | Sell |
2,334,959
-189,573
| -8% | -$21.4M | 0.59% | 46 |
|
|
2014
Q3 | $284M | Sell |
2,524,532
-102,657
| -4% | -$9.77M | 0.61% | 44 |
|
|
2014
Q2 | $249M | Sell |
2,627,189
-129,546
| -5% | -$9.08M | 0.52% | 58 |
|
|
2014
Q1 | $195M | Sell |
2,756,735
-585,666
| -18% | -$46.4M | 0.44% | 72 |
|
|
2013
Q4 | $248M | Sell |
3,342,401
-46,903
| -1% | -$3.27M | 0.55% | 55 |
|
|
2013
Q3 | $257M | Sell |
3,389,304
-260,763
| -7% | -$20.8M | 0.61% | 48 |
|
|
2013
Q2 | $292M | Buy |
+3,650,067
| New | +$269M | 0.69% | 45 |
|
Other funds holding VRTX
VCM
VPM
Lazard Asset Management's VRTX Position: Q1 2026 in Review
Lazard Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.1% in Q1 2026, buying an estimated $6.61M and bringing the position to 213,131 shares worth $95.2M. The position accounts for 0.16% of the portfolio, ranked #138.
Lazard Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $292M in Q2 2013. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Lazard Asset Management held 213,131 shares of Vertex Pharmaceuticals worth $95.2M as of Q1 2026.
- Lazard Asset Management bought 14,181 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.61M.
- Vertex Pharmaceuticals made up 0.16% of Lazard Asset Management's portfolio in Q1 2026, its #138 holding.
- Lazard Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Lazard Asset Management's Vertex Pharmaceuticals position peaked at $292M in Q2 2013.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.